Medtronic Has a Real Moat. The Problem Is It Isn't Earning Anything From It.

A surgeon stands over an open chest with a pacing lead in hand, and the rep from the device company is standing beside her - in the room, gowned, watching the screen, ready to answer a question about a product he sold and now helps deploy. This is not a sales call. It is the moat, made visible. Medtronic organizes its entire salesforce around physician specialties precisely so its people are present at the moment of decision and the moment of use, fostering relationships and selling the next device while the last one is still being implanted.² On $33.5 billion of net sales¹, that intimacy is supposed to be the thing competitors cannot copy. It mostly is. The puzzle is what it earns.

The official story is that Medtronic is a wide-moat fortress, walled in by tens of thousands of patents and an unassailable lead across medical devices. The truer story is that the moat is real but pointed in the wrong direction - it defends a plateau rather than letting the company compound from one. And the number that gives the game away is not a market share. It's the return on the capital.

A wide moat should mint money. This one doesn't.

Here is the test a real moat has to pass. A company protected from competition should earn returns on its invested capital that sit comfortably above what it costs to raise that capital - that excess is the moat, expressed in cash. Medtronic's return on invested capital is roughly 6.74%, against a broad market running near 11.03%.⁶ That is not the signature of a fortress collecting tolls. It is the signature of a business that runs hard to stay in place. Operating margin tells the same flat story: about 18.71%, essentially in line with the market's 18.32%.⁶ When a celebrated wide-moat name posts profitability indistinguishable from the average company, the label is doing more work than the business is.

This is why the moat designation itself is contested. One widely-cited analyst house has long called Medtronic wide-moat⁵; another grades it merely narrow.⁶ Both can read the same financials, which means the disagreement is really about a single question: does a moat count if it isn't producing excess returns? The honest answer is that Medtronic has built durable defenses and is spending almost all the value they generate just to maintain them.

It isn't the patents. It's the operating room.

The popular explanation reaches for the patent count - a portfolio estimated near 86,000 patents worldwide, with tens of thousands still active.⁴ Impressive, and almost beside the point. Medtronic's own annual report describes an industry 'characterized by extensive intellectual property litigation' in which the company is 'generally involved as both a plaintiff and a defendant' at any given time.² A wall you are perpetually defending in court is not a settled fortress; it is contested ground. Patents are an ingredient of the moat, not the moat itself.

What actually protects Medtronic is harder to litigate away: clinical-workflow lock-in. The salesforce is built around physician specialties to embed reps into the procedure and cross-sell across a broad portfolio.² Once a surgeon trains on a delivery system, builds muscle memory around a particular device, and relies on a rep who knows her cases, swapping that out for a rival's product carries a cost measured not in dollars but in risk, retraining, and trust. The strongest moat source isn't the IP filing - it's the intangible relationship and the muscle memory wrapped around it.⁵ You can invent around a patent. You cannot easily invent around a thousand surgeons' habits.

Three companies, one truce

The second pillar is structural, not internal. In cardiac rhythm management, Medtronic, Abbott, and Boston Scientific together hold roughly 90% of the global market.⁷ That is not a monopoly - it is a rational oligopoly, three large players who all benefit from not starting a price war. Even inside the segment Medtronic supposedly owns, dominance is narrow: it leads the implantable cardiac monitor sub-segment with only about 27.5% share, with the other two as close rivals.⁷ The protection here isn't that Medtronic crushes everyone. It's that everyone has learned it pays to compete on relationships and incremental innovation rather than price. The moat is partly a shared one, held up by all three at once - which is exactly why the returns are merely fine rather than spectacular. A truce keeps the peace; it doesn't hand any single party a windfall.

Isn't a durable plateau still a great business?

The fair objection is that this is too harsh. Medtronic grew net sales 4% to $33.5 billion and net income jumped 27% to $4.7 billion¹; it serves more than 150 countries with over 95,000 employees⁸; its return on capital, while sub-market, did rise above its own five-year average.⁶ Surely a company this entrenched, this diversified, this hard to displace, has a moat by any reasonable definition. And it does. The point is not that the moat is fake - it is that the moat's job is to produce excess returns, and this one is mostly producing stability. There is a real difference between a wall that protects compounding profits and a wall that protects a steady, average business from getting worse. Medtronic owns the second kind, and the market keeps pricing it as the first.

Worse, the strongest pillar is quietly subsiding. The very analysis that praises Medtronic's relationships also notes that the surgeon's influence on what gets bought is waning, as hospital administrators and group purchasing organizations seize procurement control.⁵ The whole switching-cost story assumes the surgeon decides. As that decision migrates from the operating room to the materials manager's spreadsheet, the relationship moat loses the person it was built around. Embedding a rep beside a surgeon matters less when the surgeon no longer signs the purchase order.

Medtronic spends almost nothing more on R&D than it did two years ago - roughly $2.7 billion, essentially flat³ - and that steadiness is the whole tell. This is a company maintaining a position, not pressing an advantage. The reps are still in the room, the patents still pile up, the three-way truce still holds. All of it works. None of it compounds. The deepest thing the anatomy reveals is that Medtronic's moat is real precisely where everyone looks past it - in habits and market structure, not in the patent count - and that its true cost is invisible on the balance sheet: it is the excess return a wide moat is supposed to deliver and this one quietly never does.